AstraZeneca’s Tagrisso (osimertinib) has been recommended for approval in the EU for treating adult patients with ...

Lung cancer treatment has witnessed a revolution in recent years, largely driven by the increasing understanding of genetics ...

If approved by the EC, Tagrisso will be the first targeted therapy for European patients with unresectable EGFR-mutated cancer.

has recommended approval of Lazcluze in combination with Rybrevant for the first-line treatment of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC). The CHMP ...

The CHMP has recommended the Rybrevant-Lazcluze combination as a first-line treatment for adult patients with locally ...

LUPKYNIS, the only FDA-approved CNI therapy for the treatment of adult patients with active LN in combination with other immunosuppressive therapies , has demonstrated broad clinical utility across ...

For patients with previously treated EGFR-mutated NSCLC, a new BLA has been submitted to the FDA seeking the accelerated ...

ArriVent BioPharma, Inc. (Nasdaq: AVBP) has announced its financial results for the third quarter of 2024, alongside ...

A new study presents a customised treatment strategy using antisense oligonucleotides (ASOs) to target EGFR mutations in ...

IgA nephropathy trials of new and emerging therapies that target B cell activity, the complement system, or the endothelin ...

Researchers used base and prime editing to uncover new EGFR gene mutations that affect cancer progression and drug resistance ...

A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from ...